Haloperidol Richter

Haloperidol, the active ingredient in Haloperidol Richter, is a butyrophenone antipsychotic presented as a unknown/unknown for oral use. It treats schizophrenia, acute psychosis, manic episodes and Tourette syndrome in adults and adolescents as prescribed.

GNH USA supplies Haloperidol Richter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Haloperidol is a dopamine D2 receptor antagonist used in the management of several psychiatric and neurological disorders. - Schizophrenia: reduces positive and negative symptoms and helps prevent relapse. - Acute psychosis: controls severe agitation and hallucinations. - Manic episodes: stabilizes mood and diminishes manic symptoms. - Tourette syndrome: lessens motor and vocal tics.

Haloperidol may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Extrapyramidal symptoms: muscle stiffness, tremor, or restlessness. - Dry mouth: reduced salivation leading to oral discomfort. - Constipation: slowed gastrointestinal motility causing hard stools.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements, especially of the face. - Cardiac arrhythmias: irregular heart rhythm, including QT prolongation.

Before prescribing haloperidol, clinicians should consider several safety and handling precautions. - Cardiac monitoring: assess ECG and QT interval, especially in patients with cardiac disease. - Metabolic risk: monitor blood glucose and lipid levels during long‑term therapy. - CNS depression: avoid concurrent use with other central nervous system depressants. - Elderly patients: use lower doses and watch for increased sensitivity to side effects. - Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Haloperidol can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antipsychotic polytherapy: combining with other dopamine antagonists can increase extrapyramidal risk. - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise haloperidol plasma levels, leading to toxicity. - QT‑prolonging agents (e.g., quinidine, sotalol): heighten risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation and respiratory depression. - Anticholinergic drugs (e.g., benztropine, trihexyphenidyl): may mask extrapyramidal symptoms. - Diabetes medications (e.g., insulin, sulfonylureas): haloperidol can affect glucose control, requiring dose adjustments.